Drug Search Results
More Filters [+]

Prinomastat

Alternative Names: prinomastat
Latest Update: 2024-03-20
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: MMP Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Prinomastat

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Non-Small-Cell Lung Cancer

Phase 2: Brain Stem Cancer|Glioblastoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

AG-3340-019

P2

Completed

Glioblastoma|Brain Stem Cancer

2002-01-01

AG-3340-017

P3

Completed

Non-Small-Cell Lung Cancer

2001-07-01

Recent News Events